Cite
HARVARD Citation
Wei, B. et al. (n.d.). 80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab. Journal for immunotherapy of cancer. pp. A49-A50. [Online].